Nektar Therapeutics

NASDAQ:NKTR

Biotechnology

Healthcare
$34.42 -2.04%

-$1.24 today

Market cap
$987.44M
Beta
1.15
P/E (TTM)
-9.3
EPS (TTM)
-$6.39
52W Low $8.27High $109.00

Volume 0.71M

Average 1.00M

NKTR Long-term Investments

Investments the company intends to hold for more than a year.

Nektar TherapeuticsNASDAQ: NKTR

Long-term Investments · Q2 FY2026 · quarter ended Jun 2026

Long-term investments rises 6239.3% from a year ago

Long-term investments stood at $340.48M at the end of Q2 FY2026, up 6239.3% from a year earlier and up 106.7% from the prior quarter.

Context

  • Long-term investments amounted to 31.1% of total assets at the end of Q2 FY2026, up 28.5 pp from a year earlier.
  • Long-term investments increased in 2 of the last 3 fiscal years.

What to watch

Whether long-term investments keeps rising in the next quarterly balance sheet after a +6239.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$340.48M+106.7% QoQ
Last fiscal yearDec 2025
$3.49M-86.6% YoY
Year agoJun 2025
$5.37M+6239.3% since
Long-term Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6239.3%——
1 year-86.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Long-term Investments history

USD · from the balance sheet

Latest · FY2025
3.49M USD
Year-over-year change
-86.6%
4-year CAGR
-51.8%

Long-term Investments vs competitors

How NKTR compares with its peers on the latest reported figures

  • Peers report in different currencies, so long-term investments is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +6239.3% is the highest of 6, against a peer median of +2.2%.
  • Long-term investments amounts to 31.1% of total assets for NKTR, versus a peer median of 2.2%.
NKTR Competitors
Long-term Investments for NKTR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NKTRNektar TherapeuticsJun 2026$340.48M USD+6239.3%—31.1%
XNCRXencor, Inc.Jun 2026$108.54M USD-58.3%+44.6%15.0%
RCUSArcus Biosciences, Inc.Jun 2026$73M USD+356.3%-40.0%7.9%
IPHAInnate Pharma S.A.Dec 2025€10.7M EUR+4.1%-32.7%17.1%
CRVSCorvus Pharmaceuticals, Inc.Mar 2026$10.5M USD-13.0%-20.5%4.1%
ANLAdlai Nortye Ltd.Dec 2025$4.25M USD+2.2%—12.3%
CGENCompugen Ltd.Mar 2026$452K USD——0.3%
IMCRImmunocore Holdings plcMar 2026$0 USD——0.0%
IMTXImmatics N.V.Mar 2026€0 EUR——0.0%
MGNXMacroGenics, Inc.Mar 2026$0 USD——0.0%
CHRSCoherus Oncology, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding NKTR) —+2.2%-26.6%2.2%

Competitors are the stored peer set for NKTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents25.22M88.23M35.28M44.25M15.12M
Short-term Investments708.74M416.75M268.34M210.97M230.64M
Net Receivables22.49M8.4M2.25M1.61M1.78M
Inventory15.8M19.2M16.1M00
Other Current Assets00000
Total Current Assets795.58M545.97M330.7M261.29M266.27M
Property, Plant & Equipment (Net)177.54M85.89M36.86M11.82M5M
Goodwill76.5M76.5M000
Intangible Assets00000
Long-term Investments64.83M025.83M26.09M3.49M
Tax Assets00000
Other Non-current Assets2.74M2.25M4.64M4.65M5.65M
Total Non-current Assets321.61M164.63M67.33M42.56M14.14M
Total Assets1.12B710.6M398.03M303.85M280.41M
Account Payables9.75M12.98M9.85M11.56M10.77M
Short-term Debt000020.5M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities15.74M9.58M5.55M5.55M22.27M
Total Current Liabilities85.2M68.2M51.27M61.4M53.54M
Long-term Debt000063.16M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities226.75M162.93M117.26M99.02M8.63M
Total Non-current Liabilities352.48M275.76M215.78M181.71M137.04M
Total Liabilities437.68M343.96M267.05M243.11M190.57M
Common Stock19K19K19K19K2K
Retained Earnings(2.83B)(3.2B)(3.48B)(3.6B)(3.76B)
Accumulated OCI(4.16M)(6.91M)80K61K17K
Other Stockholders Equity00000
Minority Interest00000
Total Equity679.51M366.64M130.99M60.74M89.83M
Total Debt143.18M131.5M117.78M102.56M148.91M
Net Debt117.96M43.27M82.5M58.31M133.79M

Nektar Therapeutics

NASDAQ:NKTR

Intrinsic Alpha fair value

Locked

Current Price

$34.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.